多种药物联合治疗白内障术后干眼症的临床效果观察

目的 探讨多种药物联合治疗白内障术后干眼症的临床疗效。方法 选取2015年5月~2018年 9 月于我院行白内障手术术后干眼患者125例,随机分为A、B、C组三组,C组患者采用玻璃酸钠滴眼液治疗,A组在C组基础上加用贝复舒滴眼液治疗,B组在C组基础上加用普拉洛芬滴眼液治疗,比较各组患者治疗前后OSDI值、BUT、SIt值、FL的变化,比较各组患者治疗前后OSDI值、BUT、SIt值、FL的变化。结果 治疗后三组患者BUT,SIt值比较,差异有统计学意义（P＜0.05）;治疗后三组OSDI值,FL比较,差异无统计学意义（P＞0.05）;B组患者治疗的总有效率（95.24%）高于A组（93.02%）及C组（87.50%）,差异有统计学意义（P＜0.05）。结论 玻璃酸钠滴眼液联合普拉洛芬滴眼液、玻璃酸钠滴眼液联合贝复舒滴眼液及单纯使用玻璃酸钠滴眼液均可减轻白内障术后干眼症患者的症状,增加泪液分泌量,延长泪膜破裂时间,使角膜染色降低,但玻璃酸钠滴眼液联合普拉洛芬滴眼液的治疗方案更佳。     

Enhanced transdermal delivery of pranoprofen from the bioadhesive gels

Percutaneous delivery of NSAIDs has advantages of avoiding hepatic first pass effect and delivering the drug for extended period of time at a sustained, concentrated level at the inflammation site that mainly acts at the joint and the related regions. To develop the new topical formulations of pranoprofen that have suitable bioadhesion, the gel was formulated using hydroxypropyl methylcellulose (HPMC) and poloxamer 407. The effects of temperature on drug release was performed at 32 degrees C, 37 degrees C and 42 degrees C according to drug concentration of 0.04%, 0.08%, 0.12%, 0.16%, and 0.2% (w/w) using synthetic cellulose membrane at 37+/-0.5 degrees C. The increase of temperature showed the increased drug release. The activation energy (Ea), which were calculated from the slope of lop P versus 1000/T plots was 11.22 kcal/ mol for 0.04%, 10.79 kcal/mol for 0.08%, 10.41 kcal/mol for 0.12% and 8.88 kcal/mol for 0.16% loading dose from the pranoprofen gel. To increase the drug permeation, some kinds of penetration enhancers such as the ethylene glycols, the propylene glycols, the glycerides, the non-ionic surfactants and the fatty acids were incorporated in the gel formulation. Among the various enhancers used, propylene glycol mono laurate showed the highest enhancing effects with the enhancement factor of 2.74. The results of this study suggest that development of topical gel formulation of pranoprofen containing an enhancer is feasible.     

普拉洛芬联合玻璃酸钠治疗中重度干眼的短期疗效

目的：评估普拉洛芬滴眼液联合玻璃酸钠滴眼液对中重度干眼治疗的短期临床疗效及对患者心理状况的影响。

方法：选取2018-01/12于我院眼科就诊并治疗的中重度干眼患者318例,采用随机数字表法将患者分为试验组(238例)和对照组(80例),其中对照组采用玻璃酸钠滴眼液治疗,试验组采用普拉洛芬滴眼液联合玻璃酸钠滴眼液治疗。治疗前、治疗后7、14、28d问卷调查患者的自觉症状及体征评分,检查结膜充血程度、泪膜破裂时间、角膜荧光素染色及泪液分泌情况,评估患者焦虑和抑郁程度。

结果：在患者的自觉症状及体征评分、结膜充血程度、泪膜破裂时间、角膜荧光素染色及泪液分泌方面,试验组在治疗后7d即有显著改善,且随着治疗时间的延长,效果更加显著,对照组在治疗后14d或28d逐渐好转; 同一治疗时间点,试验组疗效均明显优于对照组(P<0.05)。治疗后随着病情的好转,患者的焦虑或抑郁症状得到改善,试验组治疗后7d即有明显好转,对照组治疗后14d或28d逐渐好转; 同一治疗时间点,相比对照组,试验组患者的焦虑或抑郁程度均显著减轻(P<0.05)。

结论：普拉洛芬滴眼液联合玻璃酸钠滴眼液治疗干眼症起效快且疗效显著,患者自觉症状及体征显著改善,结膜充血和角膜荧光素染色减轻,泪膜破裂时间延长,泪液分泌量增加,患者焦虑或抑郁程度显著好转。     

玻璃酸钠联合普拉洛芬治疗干眼症的临床效果

目的 观察玻璃酸钠联合普拉洛芬治疗干眼症的临床效果。方法 选取我院眼科门诊于2020年 8月-2022年5月收治的80例干眼症患者作为研究对象，按照随机数字表法分为对照组和观察组，每组 40例。对照组采用玻璃酸钠治疗，观察组采用玻璃酸钠联合普拉洛芬治疗，比较两组临床疗效、临床 指标及并发症发生情况。结果 观察组治疗总有效率为97.50%，高于对照组的80.00%，差异有统计学意 义（P＜0.05）；观察组角结膜荧光素染色评分以及干眼症状评分低于对照组，泪河高度以及BUT高于对 照组，差异有统计学意义（P＜0.05）；观察组并发症发生率为2.50%，高于对照组的17.50%，差异有统计 学意义（P＜0.05）。结论 为干眼症患者实施玻璃酸钠联合普拉洛芬治疗，临床疗效理想，可有效改善患 者的眼部症状，促进泪液的分泌，且用药安全性较高。